|
Alzheimer's Disease Genetics Study Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Alzheimer's Disease Genetics Study conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Alzheimer's Disease Genetics Study Clinical research trials and Alzheimer's Disease Genetics Study medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Alzheimer's Disease Genetics Study. Alzheimer's Disease Genetics Study Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Alzheimer's Disease Genetics Study clinical trial. Subjects often receive the most expert healthcare possible for their Alzheimer's Disease Genetics Study condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Alzheimer's Disease Genetics Study  Alzheimer's Disease Genetics Study
Alzheimer's Disease Genetics Study
For Condition: Alzheimer Disease,Late Onset Alzheimer Disease
Status: Recruiting
Sponsor(s): National Institute on Aging (NIA) ,
Synopsis: The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with late onset (over 60 years of age) AD. Families meeting the criteria will have a sibling pair diagnosed with AD with an onset of age 60 or older and at least one other affected or unaffected relative willing to participate. Families will be evaluated for a medical diagnosis and other factors. If eligible, blood samples will be collected to establish cell lines. If one of the identified family members is deceased, DNA will be extracted and stored from autopsy samples. Local sites will collect clinical and demographic data from the families and will send coded data (without identifiers) to the National Cell Repository for Alzheimer's Disease (NCRAD) at Indiana University. Persons interested in registering to participate in this study can call the toll-free NCRAD number 1-800-526-2839 for more information. Local study sites are located all over the United States, and arrangements may be made for eligible families who do not live near a participating site
Details: The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with late onset (over 60 years of age) AD. Families will be evaluated for a medical diagnosis and other factors. If eligible, blood samples will be collected from the participants to establish cell lines. If one of the identified family members is deceased, DNA will be extracted and stored from autopsy samples. Qualifying families will have a minimum of 3 members participating in the study: a sibling pair diagnosed with AD with an onset at age 60 or older and a third member who must have an age of onset greater than 50, if affected, and 60 or older, if unaffected. The goal is to recruit 1,000 families in three years. This research will include a collection of samples from ethnic/minority populations and other special populations, including African Americans, the Amish, Hispanics, Asian Americans, and Japanese-Americans. Persons interested in registering to participate in this study can call the toll-free NCRAD number 1-800-526-2839 for more information. Local study sites are located all over the United States, and arrangements may be made for eligible families who do not live near a participating site. Local sites, including the NIA-sponsored Alzheimer's Disease Centers, will collect clinical and demographic data from these families, and the sites will send coded data (without identifiers) to the National Cell Repository for Alzheimer's Disease (NCRAD) at Indiana University. The biological samples and data from these families will be available to qualified researchers, who must sign a Materials Transfer Agreement (to protect the privacy rights of participants in this study and to agree to share the results of genetic analyses) before receiving DNA and data. An oversight committee known as the Cell Bank Advisory Committee (CBAC) and the Coordinator of the NIA Alzheimer's Disease Genetics Study, Richard Mayeux, MD, Columbia University, will review and monitor the process of family identification and enrollment, data collection, and the establishment of cell lines. This repository of DNA and cell lines was developed in hopes of discovering risk factor genes that contribute to late onset AD.
Eligibility:
Study Type: Observational, Cross-Sectional
Minimum Age/Maximum Age: 50 Years/
Genders: Both
Protocol Entry Criteria: Families meeting the criteria will have a sibling pair diagnosed with AD with an onset age of 60 or older and at least one other affected or unaffected relative willing to participate. There must be at least three individuals in the family for whom biological samples are available. a) First Family Member (proband): - A diagnosis of definite or probable AD by NINDS-ADRDA criteria. - Age at onset or age at diagnosis of > 60 years. - Individual was evaluated in person and diagnosed by an NIA-funded Alzheimer's Disease Center. - Biological samples available. b) Second Family Member: - A sibling of the proband. - A diagnosis of Definite AD, Probable AD, or Possible AD by NINDS-ADRDA criteria. - Age of onset or age at diagnosis > 60 years. - Preferred that individual be evaluated in person, but a diagnosis by medical records (including dementia testing) and telephone interview is acceptable. - Biological samples available. c) Third Family Member: - A sibling, half-sibling, parent, offspring, aunt, uncle, or first cousin of the proband. - A diagnosis of Definite AD, Probable AD, Possible AD by NINDS-ADRDA criteria; a diagnosis of questionable dementia; mild cognitive impairment; or unaffected by AD. - If affected, age of onset of dementia or age at diagnosis > 50 years. - If unaffected, must be > 60 years. - Preferred that the individual be evaluated in person, but a diagnosis (including cognitive testing) by medical records/telephone interview is acceptable. - Biological samples available. d) Biological samples: - Fresh blood, or - Immortalized lymphoblastic cell lines, or - 3-5 grams of frozen cerebral cortex; fixed samples are not accepted
Total Enrollment: 3000
Location and Contact Information:
Overall Study Official:
TatianaForoud, Principal Investigator, National Cell Repository for Alzheimer's Disease (NCRAD), Indiana University
National Cell Repository for Alzheimer's Disease (NCRAD), Indiana University *Recruiting*
Indianapolis, Indiana, 46202-5251
United States
Recruiting Jamalynne Stuck 317-274-7360
Additional Information:
Study ID Numbers: IA0042; NIH grant U24 AG21886
Study Start Date: June 2002
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00064870
Other Alzheimer Disease Studies:
1. Alzheimer's Disease Genetics Study
Related Studies:
Other Alzheimer Disease Clinical Trials
Other Indiana Clinical Trials
Other Indianapolis Clinical Trials
Alzheimer's Disease Genetics Study
|
|
|
|
|
|
|
|
